A comparative propensity score-matched analysis of perioperative outcomes of intracorporeal vs extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium.


Journal

BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721

Informations de publication

Date de publication:
08 2020
Historique:
pubmed: 20 4 2020
medline: 18 12 2020
entrez: 20 4 2020
Statut: ppublish

Résumé

To compare the perioperative outcomes of intracorporeal (ICUD) vs extracorporeal urinary diversion (ECUD) after robot-assisted radical cystectomy (RARC). We retrospectively reviewed the prospectively maintained International Robotic Cystectomy Consortium (IRCC) database. A total of 972 patients from 28 institutions who underwent RARC were included. Propensity score matching was used to match patients based on age, gender, body mass index (BMI), American Society of Anesthesiologists Score (ASA) score, Charlson Comorbidity Index (CCI) score, prior radiation and abdominal surgery, receipt of neoadjuvant chemotherapy, and clinical staging. Matched cohorts were compared. Multivariate stepwise logistic and linear regression models were fit to evaluate variables associated with receiving ICUD, operating time, 90-day high-grade complications (Clavien-Dindo Classification Grade ≥III), and 90-day readmissions after RARC. Utilisation of ICUD increased from 0% in 2005 to 95% in 2018. The ICUD patients had more overall complications (66% vs 58%, P = 0.01) and readmissions (27% vs 17%, P = 0.01), but not high-grade complications (21% vs 24%, P = 0.22). A more recent RC era and ileal conduit diversion were associated with receiving an ICUD. Higher BMI, ASA score ≥3, and receiving a neobladder were associated with longer operating times. Shorter operating time was associated with male gender, older age, ICUD, and centres with a larger annual average RC volume. Longer intensive care unit stay was associated with 90-day high-grade complications. Higher CCI score, prior radiation therapy, neoadjuvant chemotherapy, and ICUD were associated with a higher risk of 90-day readmissions. Utilisation of ICUD has increased over the past decade. ICUD was associated with more overall complications and readmissions compared to ECUD, but not high-grade complications.

Identifiants

pubmed: 32306494
doi: 10.1111/bju.15083
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-272

Informations de copyright

© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.

Références

Hautmann RE, de Petriconi RC, Volkmer BG. 25 years of experience with 1,000 neobladders: long-term complications. J Urol 2011; 185: 2207-12
Hussein AA, Hashmi Z, Dibaj S et al. Reoperations following robot-assisted radical cystectomy: a decade of experience. J Urol 2016; 195: 1368-76
Khan MS, Gan C, Ahmed K et al. A single-centre early phase randomised controlled three-arm trial of open, robotic, and laparoscopic radical cystectomy (CORAL). Eur Urol 2016; 69: 613-21
Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi RS. Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 2010; 57: 196-201
Bochner BH, Dalbagni G, Sjoberg DD et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol 2015; 67: 1042-50
Jonsson MN, Adding LC, Hosseini A et al. Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with transitional cell carcinoma of the bladder. Eur Urol 2011; 60: 1066-73
Ahmed K, Khan SA, Hayn MH et al. Analysis of intracorporeal compared with extracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2014; 65: 340-7
Hussein AA, May PR, Jing Z et al. Outcomes of intracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol 2018; 199: 1302-11
Hussein AA, Dibaj S, Hinata N et al. Development and validation of a quality assurance score for robot-assisted radical cystectomy: a 10-year analysis. Urology 2016; 97: 124-9
Azzouni FS, Din R, Rehman S et al. The first 100 consecutive, robot-assisted, intracorporeal ileal conduits: evolution of technique and 90-day outcomes. Eur Urol 2013; 63: 637-43
Tan WS, Sridhar A, Goldstraw M et al. Robot-assisted intracorporeal pyramid neobladder. BJU Int 2015; 116: 771-9
Hussein AA, Ahmed YE, Kozlowski JD et al. Robot-assisted approach to ‘W’-configuration urinary diversion: a step-by-step technique. BJU Int 2017; 120: 152-7
Hautmann RE, Abol-Enein H, Lee CT et al. Urinary diversion: how experts divert. Urology 2015; 85: 233-8
Desai MM, Gill IS. The devil is in the details": randomized trial of robotic versus open radical cystectomy. Eur Urol 2015; 67: 1053-5
Smith AB, Raynor M, Amling CL et al. Multi-institutional analysis of robotic radical cystectomy for bladder cancer: perioperative outcomes and complications in 227 patients. J Laparoendosc Adv Surg Tech 2012; 22: 17-21
Hussein AA, May PR, Ahmed YE et al. Development of a patient and institutional-based model for estimation of operative times for robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 2017; 120: 695-701
Filson CP, Tan HJ, Chamie K, Laviana AA, Hu JC. Determinants of radical cystectomy operative time. Urol Oncol 2016; 34: 431.e17-24
Kiran RP, Ali UA, Coffey JC, Vogel JD, Pokala N, Fazio VW. Impact of resident participation in surgical operations on postoperative outcomes: National Surgical Quality Improvement Program. Ann Surg 2012; 256: 469-75
Bertolo R, Agudelo J, Garisto J, Armanyous S, Fergany A, Kaouk J. Perioperative outcomes and complications after robotic radical cystectomy with intra-corporeal or extra-corporeal ileal conduit urinary diversion: head-to-head comparison from a single-institutional prospective study. Urology 2019; 129: 98-105
Elsayed AS, Aldhaam NA, Brownell J et al. Perioperative and oncological outcomes of robot-assisted radical cystectomy in octogenarians. J Geriatr Oncol 2019 [Epub ahead of print]. https://doi.org/10.1016/j.jgo.2019.07.010
Yuh BE, Ciccone J, Chandrasekhar R et al. Impact of previous abdominal surgery on robot-assisted radical cystectomy. JSLS 2009; 13: 398
Eijkemans MJ, Van Houdenhoven M, Nguyen T, Boersma E, Steyerberg EW, Kazemier G. Predicting the unpredictable: a new prediction model for operating room times using individual characteristics and the surgeon's estimate. Anesthesiology 2010; 112: 41-9
Linder BJ, Frank I, Cheville JC et al. The impact of perioperative blood transfusion on cancer recurrence and survival following radical cystectomy. Eur Urol 2013; 63: 839-45
Yuh BE, Nazmy M, Ruel NH et al. Standardized analysis of frequency and severity of complications after robot-assisted radical cystectomy. Eur Urol 2012; 62: 806-13
Ahmed YE, Hussein AA, May PR et al. Natural history, predictors and management of ureteroenteric strictures after robot assisted radical cystectomy. J Urol 2017; 198: 567-74
Catto JW, Khetrapal P, Ambler G et al. Robot-assisted radical cystectomy with intracorporeal urinary diversion versus open radical cystectomy (iROC): protocol for a randomised controlled trial with internal feasibility study. BMJ Open 2018; 8: e020500
Aldhaam NA, Elsayed AS, Jing Z et al. Neoadjuvant chemotherapy is not associated with adverse perioperative outcomes after robot-assisted radical cystectomy: a case for increased use from the IRCC. J Urol 2020;203:57-61.

Auteurs

Ahmed A Hussein (AA)

Roswell Park Cancer Institute, Buffalo, NY, USA.

Ahmed S Elsayed (AS)

Roswell Park Cancer Institute, Buffalo, NY, USA.

Naif A Aldhaam (NA)

Roswell Park Cancer Institute, Buffalo, NY, USA.

Zhe Jing (Z)

Roswell Park Cancer Institute, Buffalo, NY, USA.

James O Peabody (JO)

Henry Ford Health System, Detroit, MI, USA.

Carl J Wijburg (CJ)

Rijnstate Hospital, Arnhem, The Netherlands.

Andrew Wagner (A)

Beth Israel Deaconess Medical Center, Boston, MA, USA.

Abdullah Erdem Canda (AE)

Ankara Ataturk Training and Research Hospital, Yildirim Beyazit University, Ankara, Turkey.

Mohammad Shamim Khan (MS)

Guy's Hospital and King's College London School of Medicine, London, UK.

Douglas Scherr (D)

Weill Cornell Medical Center, New York, NY, USA.

Francis Schanne (F)

Urological Surgical Associates of Delaware, Wilmington, DE, USA.

Thomas J Maatman (TJ)

Metro Health Hospital, Michigan State University, East Lansing, MI, USA.

Eric Kim (E)

Washington University, St. Louis, MO, USA.

Alexandre Mottrie (A)

Onze-Lieve-Vrouw Ziekenhuis, Aalast, Belgium.

Ahmed Aboumohamed (A)

Montefiore Medical Center, The Albert Einstein College of Medicine, New York, NY, USA.

Franco Gaboardi (F)

San Raffaele Turro Hospital, Milan, Italy.

Giovannalberto Pini (G)

San Raffaele Turro Hospital, Milan, Italy.

Jihad Kaouk (J)

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.

Bertram Yuh (B)

City of Hope and Beckman Research Institute, Duarte, CA, USA.

Koon-Ho Rha (KH)

Department of Urology, Yonsei University Health System Severance Hospital, Seoul, Korea.

Ashok Hemal (A)

Wake Forest University Baptist Medical Center, Winston-Salem, NC, USA.

Joan Palou Redorta (J)

Fundacio Puigvert, Barcelona, Spain.

Ketan Badani (K)

Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.

Matthias Saar (M)

University of the Saarland, Homburg Saar, Germany.

Michael Stockle (M)

University of the Saarland, Homburg Saar, Germany.

Lee Richstone (L)

The Arthur Smith Institute for Urology, New Hyde Park, NY, USA.

Morgan Roupret (M)

Pitie Salpetriere Academic Hospital, Sorbonne University, Paris, France.

Derya Balbay (D)

Koç University Hospital, Istanbul, Turkey.

Prokar Dasgupta (P)

Guy's Hospital and King's College London School of Medicine, London, UK.

Mani Menon (M)

Henry Ford Health System, Detroit, MI, USA.

Khurshid A Guru (KA)

Roswell Park Cancer Institute, Buffalo, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH